first-line

You have access
First-Line Gemcitabine, Nab-Paclitaxel, and Oxaliplatin Chemotherapy With Itraconazole in Patients With Metastatic Pancreatic Cancer: A Single Institution Experience
MIYUKI SAWASAKI, HIROSHI TSUBAMOTO, AYAKO SUGIHARA, SHINICHI IKUTA, YOSHIYUKI SAKAI, YUKIO OSAKI and TAKASHI SONODA

Anticancer Research December 2022, 42 (12) 6063-6069; DOI: https://doi.org/10.21873/anticanres.16118
You have access
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI and ANDREA BONETTI

Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550
You have access
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
ANDREA SBRANA, ELISA BIASCO, FEDERICO PAOLIERI, ERICA PALESANDRO, CLAUDIA CASERTA, ROBERTO IACOVELLI, BEATRICE DETTI, DANIELE SANTINI, ALESSANDRA MOSCA, FRANCO MORELLI, GIUSEPPE FORNARINI, UGO DE GIORGI, CRISTINA MASINI and LUCA GALLI

Anticancer Research August 2018, 38 (8) 4913-4918; DOI: https://doi.org/10.21873/anticanres.12807
You have access
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
VERONIQUE DIERAS, SIMONA POP, FREDERIQUE BERGER, MARIE-EGLANTINE DUJARIC, PHILIPPE BEUZEBOC, LAURENCE ESCALUP, FRANÇOIS CLEMENT BIDARD, PAUL HENRI COTTU, CHRISTOPHE LE TOURNEAU, SOPHIE PIPERNO-NEUMANN, VALERIE LAURENCE, MATHIEU ROBAIN, BERNARD ASSELAIN and JEAN-YVES PIERGA

Anticancer Research March 2017, 37 (3) 1403-1407;
You have access
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study
ANDREAS SCHNEEWEISS, FRANK FÖRSTER, HANS TESCH, BAHRIYE AKTAS, OLEG GLUZ, MATTHIAS GEBERTH, MARTIN M. HERTZ-EICHENRODE, WINFRIED SCHÖNEGG, CLAUDIA SCHUMACHER, ANDREAS KUTSCHEIDT, CLAUDIA KIEWITZ, SANDRA KLAWITTER and MARCUS SCHMIDT

Anticancer Research March 2016, 36 (3) 967-974;
You have access
Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
TETSUYA KUBOTA, YOSHIO OKANO, MIZU SAKAI, MASATO TAKAOKA, TSUKIE TSUKUDA, KAZUKI ANABUKI, SHIGEO KAWASE, SHINTARO MIYAMOTO, HIROSHI OHNISHI, NOBUO HATAKEYAMA, HISANORI MACHIDA, TOMOYUKI URATA, AKIRA YAMAMOTO, FUMITAKA OGUSHI and AKIHITO YOKOYAMA

Anticancer Research January 2016, 36 (1) 307-312;
You have access
No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA

Anticancer Research May 2015, 35 (5) 3067-3073;
You have access
First-line Bevacizumab–Paclitaxel in 220 Patients with Metastatic Breast Cancer: Results from the AVAREG Study
MAGDOLNA DANK, LASZLO BUDI, BELA PIKO, LASZLO MANGEL, JOZSEF ERFAN, JOZSEF CSEH, AGNES RUZSA and LASZLO LANDHERR

Anticancer Research March 2014, 34 (3) 1275-1280;
You have access
Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer
ARLENE CHAN, PIER-FRANCO CONTE, LUBOS PETRUZELKA, NICOLE TUBIANA-MATHIEU, VINOD GANJU, ANTONIO LLOMBART, MARC ESPIE, FRANÇOISE MAJOIS, MIGUEL GIL GIL, NATHALIE VAISSIERE and GUSTAVO VILLANOVA

Anticancer Research June 2013, 33 (6) 2657-2664;

Main menu

User menu

Search

first-line